Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Fractyl Health

Fractyl Health Demonstrated Significant Improvement in Weight Loss in Head-to-Head Preclinical Obesity Studies of its Rejuva® GLP-1-Based Pancreatic Gene Therapy Candidate (GLP-1 PGTx) Compared to Chronic Semaglutide at EASD’s Annual Meeting
From Fractyl Health
Via Business Wire
Fractyl Health to Present Pioneering Data on Revita® and Rejuva® Programs at the European Association for the Study of Diabetes (EASD) 2023 Scientific Congress
From Fractyl Health
Via Business Wire
Fractyl Health Welcomes Dr. Timothy Kieffer as Chief Scientific Officer
From Fractyl Health
Via Business Wire
Fractyl Health Mourns the Passing of Esteemed Board Member Brian Dovey
From Fractyl Health
Via Business Wire
Fractyl Health Announces Clinical Update on Revita® Real World Registry in Germany and Launch of Revita+™ Telehealth Program Combining Behavioral Recommendations with Revita Treatment for Type 2 Diabetes
From Fractyl Health
Via Business Wire
Fractyl Health Reports Durable Improvement in Glucose Control, Weight Loss, and Insulin Reduction in T2D Patients Using Revita® in Open Label Phase of Revitalize 1 Pivotal Study at the American Diabetes Association 83rd Scientific Sessions
From Fractyl Health
Via Business Wire
Fractyl Health Demonstrates Significant Improvement in Glucose Control and Obesity in Preclinical Studies of its Rejuva® GLP-1 Based Pancreatic Gene Therapy (GLP1 PGTx) Compared to Chronic Semaglutide at ADA's 83rd Scientific Sessions
From Fractyl Health
Via Business Wire
Fractyl Health to Present Landmark Updates on Revita® and Rejuva® Programs at the 83rd American Diabetes Association
From Fractyl Health
Via Business Wire
Fractyl Health Unveils Groundbreaking Pre-Clinical Proof of Concept Results for its Rejuva® Pancreatic Gene Therapy Platform for Metabolic Diseases at the American Society of Gene & Cell Therapy Congress
From Fractyl Health
Via Business Wire
Fractyl Health to Present Preclinical Proof-of-Concept Data for Rejuva® Pancreatic Gene Therapy Platform Program at the American Society of Gene & Cell Therapy Congress
From Fractyl Health
Via Business Wire
Fractyl Health to Present Scientific Updates on Revita® and Rejuva® Programs at Upcoming Medical Congresses
From Fractyl Health
Via Business Wire
Fractyl Health Announces the Initiation of a Global Registry Study of the Revita System™ in Patients With Inadequately Controlled Type 2 Diabetes (T2D)
From Fractyl Health
Via Business Wire
Fractyl Health Announces Commercial Availability of Revita® in Germany and Successful First Procedure at 25th Düsseldorf International Endoscopy Symposium
From Fractyl Health
Via Business Wire
Fractyl Health Provides Clinical Update on 24-Week Data from Open Label REVITA-T2Di Cohort
From Fractyl Health
Via Business Wire
Fractyl Health Announced Positive Proof-of-Concept Data of Pancreatic GLP-1 Gene Therapy in a Type 2 Diabetes Animal Model at the 20th World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease
From Fractyl Health
Via Business Wire
Fractyl Health Initiates Landmark Scientific Partnership to Study Root Cause Mechanisms Underlying Type 2 Diabetes
From Fractyl Health
Via Business Wire
Fractyl Health Presents New Mechanistic Data on Revita® DMR in Type 2 Diabetes
From Fractyl Health
Via Business Wire
Fractyl Health to Present New Data on Revita® DMR in Type 2 Diabetes at Digestive Disease Week 2022
From Fractyl Health
Via Business Wire
Fractyl Health Announces FDA IDE Approval to Begin Revitalize-2 Pivotal Study Designed for Patients with Type 2 Diabetes (T2D) Who Are Not Yet on Insulin
From Fractyl Health
Via Business Wire
Fractyl Health Receives Reimbursement Authorization in Germany for Revita DMR® System
From Fractyl Health
Via Business Wire
Fractyl Health Publishes Two-Year Durability Data After a Single Revita DMR® Therapeutic Procedure in Patients with Type 2 Diabetes
From Fractyl Health
Via Business Wire
Fractyl Health Provides Initial Clinical Update on Open-Label REVITA-T2Di
From Fractyl Health
Via Business Wire
Fractyl Health Appoints Kelly Barnes to the Company’s Board of Directors
From Fractyl Health
Via Business Wire
Fractyl Health Announces the FDA’s Authorization of Expanding the Revitalize-1 Study’s Sample Size
From Fractyl Health
Via Business Wire
Fractyl Health Announces Publication of Pioneering New Model of Intestine’s Role in Metabolism
From Fractyl Health
Via Business Wire
Fractyl Announces Tenth Trial Site Opened in REVITA-T2Di Study of Revita® DMR for Type 2 Diabetes
From Fractyl Health
Via Business Wire
Fractyl Announces Closing of $100 Million Series F Financing to Expand Clinical Development Programs in Type 2 Diabetes
From Fractyl Health
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.